Technology Appraisal Guidance No. 296
Source: National Institute for Health and Care Excellence
1.1 Crizotinib is not recommended within its marketing authorisation, that is, for treating adults with previously treated anaplastic-lymphoma-kinase-positive advanced non-small-cell lung cancer.
1.2 People currently receiving crizotinib that is not recommended according to 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA296
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene.
Issue Date: September 2013